Proteomics is innovating medicine on a weekly, if not daily basis. The study of proteins and their function in our systems is constantly revealing new truths about our bodies, our diseases, and potential treatment options. IMCS is so proud to play a role in the advancement of this science.
Thanks to recent technological developments in proteomics, more and more researchers and geneticists are making discoveries every year. Some of these discoveries will have profound effects on our health.
Here are four recent proteomic milestones to watch in the coming years.
- Identifying IBS through bio-markers.
In the past three years, huge strides have been made globally in identifying specific biomarkers for IBS and other gastrointestinal diseases. Fifteen biomarkers including plasma citrulline, fecal calprotectin, and HBD2 have shown great potential as reliable indicators of disease. Researchers are currently in the process of developing multi-domain biomarker panels to use in conjunction with traditional tissue sampling methods which they hope will produce the most accurate picture of GI distress available.
- Protein-coding as a predictor of Alzheimer’s.
Scientists have known for decades that microglia, natural defense cells, are a pathological purveyor of Alzheimer’s-related protein damage. What has not been known until recently is which gene/protein combinations in the body make humans most susceptible to developing the disease. Scientists at the University of Bradford are making exciting headway in protein capture, a process that can ultimately help identify the particular proteins involved in the Alzheimer’s mutation process.
- Dolphin gene mapping.
Dolphins and humans share dozens of mammalian proteins. Marine scientists in Charleston, S.C., recently discovered that the genome of the bottlenose dolphin offers a lot of useful information for researchers working on the human genome. By highlighting some of the overlaps between the human protein map and the dolphin protein map, specifically, scientists at the Hollings Marine Laboratory hope to shed new light on proteomic questions that have plagued medical researchers for years.
- Protein isolation for depression and anxiety.
In late 2016, researchers in Finland made a startling discovery: by hindering a specific protein called JNK, they could reduce the occurrence of mood disorders such as anxiety and depression in mice. The catch is that the JNK inhibitors only work when applied specifically to newly generated nerve cells directly in the hippocampus. Further study on humans is needed, but researchers are hopeful that the JNK protein may indeed be the key to developing better, more pointed inhibiting medication.
Proteomics doesn’t exist in a vacuum. The study of proteins is most useful when it overlaps with genomics and other biological disciplines. IMCS is committed to creating products that make advancing proteomics more feasible and more attainable for labs across the world.
To find out more about IMCS’s revolutionary proteomic technology, please browse useful resources here, or reach out to one of our specialists today. We’re happy to work with you on an application that improves your process.